Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54388
Title: MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
Authors: 
Filiation: Servicio de Neurología. Hospital Universitario de Fuenlabrada
Keywords: 
Mesh: 
Issue Date: 17-Jul-2021
Citation: J Headache Pain.2021 Jul;(22)1:74
Abstract: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a prospective registry to evaluate real-world effectiveness and tolerability, and all Spanish headache experts were invited to participate. We present their first results.
PMID: 34273947
URI: https://hdl.handle.net/20.500.12530/54388
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Journal Headache Pain.pdf761,94 kBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons